A biotech closes a $45 million Series B. The alert lands on your dashboard the morning it is announced, and you run the standard play: pull the executive team, find whoever owns the function you sell into, and send a note congratulating them on the round. Then nothing. The problem usually is not the email.
It is that you have walked into a spending sequence that was decided weeks before the announcement, and what a clinical-stage company buys in its first quarter after a raise looks almost nothing like what a newly funded software company buys.
The Clock Is the Whole Story
Software startups spend post-raise capital on growth. Clinical-stage biotechs spend it on a trial that has a start date, and that start date is the number the board is watching. Every day between the money landing and the first patient enrolling is a day of burn with no data coming back.
The cost of that time is measurable. Tufts CSDD analyzed budgets from 447 protocols and found that the direct daily cost of running a trial averages roughly $40,000 across Phase II and Phase III, with Phase III at $55,716 per day and Phase II at $23,737. Phase I runs $7,829. Those are direct trial costs alone, and they accrue whether the study is producing usable data or sitting idle while waiting for infrastructure that is not ready.
So, the question worth asking about a newly funded biotech is not what it needs. It is what has to exist before the first patient can be enrolled, because that is the list that gets bought first.
Where the Money Actually Goes
The Office of the Assistant Secretary for Planning and Evaluation at HHS commissioned a detailed breakdown of clinical trial cost components by phase, built from negotiated investigator grants and CRO contracts across thousands of studies. The average total per-study cost came to $3.8 million for Phase I, $13.35 million for Phase II, and $19.89 million for Phase III.
More useful than the totals is how that report groups the spending. Some costs are per patient: recruitment, clinical procedures, and nursing. Some are per site: monitoring, retention, and project management. Others are per study, incurred once at the study level regardless of how many patients or sites eventually participate. Data collection, management, and analysis sit in that last group, alongside IRB approvals and source data verification.
Per-study costs get committed earliest because they are structural. You cannot activate a site or enroll a patient into a study whose data architecture does not yet exist.
The same report identifies source data verification as a surprisingly heavy line item: in Phase I, it accounts for more than 15 percent of the itemized per-study subtotal. SDV is the manual work of checking entered data against original records, and how much of it a study needs depends heavily on how the data was captured in the first place.
That connection is why the data decision carries weight beyond its own price tag. The ASPE analysis modeled which changes to trial conduct could reduce costs, and wider use of digital data collection emerged as one of the most effective interventions available, with modeled per-trial savings reaching $0.4 million in Phase I, $2.4 million in Phase II, and $6.1 million in Phase III.
For a company with eighteen months of runway, that is not a procurement footnote. It is a line on the burn chart.
What Gets Contracted Before the First Patient
Once the protocol is locked, the sequence is fairly predictable. The sponsor selects a CRO or staffs internal clinical operations. Regulatory submissions go in. The data system is chosen, configured, and validated. Sites are contracted and activated. Then, and only then, does enrollment open.
Electronic data capture replaces paper forms with electronic case report forms that investigators complete directly, with validation rules and logic checks built into the forms so that mistakes surface at entry instead of during cleanup months later. Building those forms is not simply a purchase followed by a login. Every form must be designed against the protocol, configured, tested, and validated before it can hold regulated data.
A team that selects a platform late does not just pay more; it moves the first-patient-in date.
That is why the vendor conversation happens early in the post-raise window and why a representative who arrives two months after the funding announcement is often speaking to a company that has already signed.
It is also worth knowing that adoption is not yet universal. The ASPE report notes that not every sponsor has replaced paper records, and industry inertia is rooted less in cost than in perceived regulatory risk, with teams repeating processes that worked before rather than adopting alternatives that could save time.
Small companies coming off a first institutional round are frequently the ones running spreadsheets and paper case report forms because that is what the founding scientists used in the lab. They are, in other words, an unusually active prospect group at the moment their trial scope outgrows their existing processes.
Reading the Signal at the Right Resolution
Funding alerts work because timing correlates with buying. Forrester research cited in Fundz’s own guide puts the conversion lift from acting on trigger events as high as 400 per cent.
However, an alert is a starting gun, not a brief. Two biotechs that each raised $40 million last month can occupy completely different procurement positions depending on where they are in development.
The gap between Series A versus Series B funding stages matters more in this sector than in most. A Series A biotech is often still preclinical or entering Phase I, buying lean and establishing clinical infrastructure for the first time.
A Series B or C company is scaling an existing program, which means it already has vendors and the opening is not a greenfield sale but a displacement or an expansion into a second study. The same alert requires a different conversation and a different opening line.
The Buyer Is Not Who Your CRM Suggests
At a clinical-stage company, the person evaluating a data system is usually a director of clinical operations or clinical data management, often with quality assurance holding an effective veto over anything that touches regulated records. The CEO of a 35-person biotech is running the raise and the pipeline. The CFO is managing the runway. Neither is necessarily forwarding your note to the person who would actually use the product.
Those people are findable, and their arrival is a signal in its own right. A biotech that has just posted a job requisition for a clinical data manager is a biotech preparing to buy the tools that a clinical data manager uses. Executive hires in clinical operations, regulatory affairs, and quality carry more purchasing information in this sector than a new commercial leader because they indicate which function is being built next and on what timeline.
It also helps to do the runway arithmetic before writing anything. A company running a single Phase II study at $23,737 per day is spending approximately $8.7 million a year in direct trial costs alone, before salaries, facilities, or manufacturing. Against a $45 million raise, that calculation explains why the buying committee treats a delay of even a few weeks as expensive and why it may pay attention to a message that speaks to the timeline rather than the price.
Conclusion
Life sciences rounds behave differently from software rounds, and treating them the same is why so much biotech outreach lands badly. The capital is committed against a trial timeline, not a growth plan.
Structural per-study costs, including the data infrastructure on which the entire trial runs, are locked in before site activation and long before headcount scales. The people who make those decisions also sit two or three levels below the names appearing in the funding announcement.
For anyone working with funding alerts in this sector, that leads to a practical adjustment. Read the stage, not just the dollar figure. Move inside the pre-enrollment window rather than arriving after it. Target clinical operations and data management directly. Trials burn tens of thousands of dollars a day, whether or not they are generating data, and every vendor decision made during that window is made against that clock.
Frequently Asked Questions About Electronic Data Capture in Biotech Trials
The following questions address the practical sequencing, evaluation, and governance decisions that newly funded sponsors should consider before committing to an electronic data capture platform.
What should a biotech define before selecting an EDC vendor?
The sponsor should document the study design, expected site count, planned patient population, data-review responsibilities, reporting needs, and any systems that will need to exchange information with the EDC platform. It should also identify who owns form design, testing, validation, change control, and user training.
Defining these responsibilities before procurement makes proposals easier to compare and reduces the risk of discovering costly gaps after configuration has begun.
How early should EDC selection begin?
Requirements gathering can begin while the protocol is still being finalized, provided the team recognizes that major protocol changes may affect the final configuration. Vendor selection, contracting, form design, testing, and validation should leave enough time for the system to be ready before site activation and investigator training.
Working backward from the planned first-patient-in date is usually more useful than treating EDC as a task that begins after the protocol is complete.
Which EDC capabilities matter most for a small biotech sponsor?
A small sponsor should prioritize reliable audit trails, configurable validation rules, straightforward data exports, role-based access, responsive technical support, and a manageable validation process.
Features that shorten study setup or reduce manual reconciliation may create more value than a large catalogue of enterprise functions that the team will not use. The right platform is the one that meets the study’s operational and quality requirements without introducing unnecessary complexity.
How can a biotech measure whether its EDC implementation is reducing risk?
Useful measures include the time required to build and approve forms, the interval between site activation and first patient in, data-entry lag, query volume, query-resolution time, and the amount of manual reconciliation required.
The team can also monitor recurring form errors, late data, protocol-related changes, and support requests across sites. Establishing baseline expectations before launch makes it easier to distinguish genuine improvement from ordinary study variation.
Which EDC contract terms deserve the closest attention?
The agreement should clearly define implementation responsibilities, validation deliverables, support levels, data ownership, export formats, change-request pricing, user or site limits, and access to data after the study ends. Sponsors should also understand which services are included in the quoted price and which will trigger additional fees as the trial changes.
A lower license price may offer little value if configuration, migration, support, or study-closeout costs remain unclear.